RxDoctor Payments Data

Charles Raine, MD

Endocrinology, Diabetes & Metabolism · Orangeburg, SCNPI 1255393211

Payments from drug & device makers

What this record shows

Sanofi-aventis U.S. LLC accounts for 61.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2020 at $2,154 and has fallen 93.3% since, to $144 in 2025.

$3,635in general payments, 2019–2025

Across 83 payments — averaging $43.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$2K
  • Insulet Corporation$540
  • Lilly USA, LLC$285
  • Corcept Therapeutics$136
  • Mannkind Corporation$119
  • Valeritas, Inc.$101
  • plus $222 from 9 others

What the payments were for

  • Speaking & faculty fees$1,99455%
  • Food & beverage$1,64245%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,635 in reported general payments places this provider in the 55th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

See all endocrinology, diabetes & metabolism providers in South Carolina

Medicare billing

Part B allowed, 2024
$61,027
Medicare patients
110
Services billed
467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide84$115,267
TrulicityDulaglutide104$111,505
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/788$89,325
OzempicSemaglutide62$72,808
JardianceEmpagliflozin61$64,686
FarxigaDapagliflozin Propanediol92$57,251
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog67$45,499
JanuviaSitagliptin Phosphate45$40,647
RybelsusSemaglutide42$37,733
Humalog Kwikpen U-200Insulin Lispro32$30,344
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$29,424
Janumet XrSitagliptin Phos/Metformin Hcl36$27,940
JanumetSitagliptin Phos/Metformin Hcl21$19,362
Lyumjev Kwikpen U-200Insulin Lispro-Aabc16$16,865
Lyumjev Kwikpen U-100Insulin Lispro-Aabc22$16,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog$285$257,510269 claims
Novo NordiskOzempic, Rybelsus, Novolog$14$115,793130 claims
MerckJanuvia, Janumet Xr, Janumet$38$87,948102 claims
Boehringer IngelheimJardiance, Synjardy, Tradjenta$41$87,49195 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

Other endocrinology, diabetes & metabolism in Orangeburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →